REGN · News · 20260805N

Revenue Performance and Mix

REGENERON PHARMACEUTICALS, INC. · 2026-08-05 · Importance 24 · Surprise 14

Regeneron reported Q2 2026 revenue of $4.29 billion, exceeding analyst expectations. Diluted EPS was $14.29 for the quarter. Revenue increased year over year, while net income and diluted EPS declined sequentially or year over year, according to the report. The mixed results reflected higher sales alongside softer profitability.

Key facts

• Regeneron reported Q2 2026 EPS of $14.29 and revenue of $4.29 billion, beating analyst expectations. source
• MassMutual Private Wealth & Trust FSB reduced its stake in Regeneron by 12.9% in the second quarter, selling 1,424 shares and retaining 9,576 shares valued at $5.97 million. source